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A new adjunctive Tx option  
for venous stasis ulcers
Adding simvastatin to standard wound care improves 
ulcer healing rates and times as well as the patient’s 
quality of life. 
PRACTICE CHANGER 
Consider adding simvastatin 40 mg/d to stan-
dard wound care and compression for pa-
tients with venous stasis ulcers.1
StReNGtH oF ReCoMMeNDAtioN
B: Based on a high-quality randomized con-
trolled trial (RCT).
Evangelista MT, Casintahan MF, Villafuerte LL. Simvastatin as a novel 
therapeutic agent for venous ulcers: a randomized, double-blind, pla-
cebo-controlled trial. Br J Dermatol. 2014;170:1151-1157.
ILLUSTRATIVE CASE
a 74-year-old woman with chronic lower ex-
tremity edema seeks treatment for a nonheal-
ing venous stasis ulcer. for the past 9 months, 
she’s been wearing compression stockings and 
receiving intermittent home-based wound 
care, but nothing seems to help. She asks if 
there’s anything else she can try.
Venous stasis ulcers affect 1% of US adults and lead to substantial mor-bidity and more than $2 billion in 
annual health care expenditures.1,2 Edema 
management—generally limb elevation and 
compression therapy—has been the main-
stay of therapy. Treatment can be lengthy, 
and ulcer recurrences are common.2,3
Statins have been found to help wound 
healing through their diverse physiologic 
(pleiotropic) effects. Evidence shows they 
can be beneficial for treating diabetic foot ul-
cers,4 pressure ulcers,5 and ulcerations asso-
ciated with systemic sclerosis and Raynaud’s 
phenomenon.6 Evangelista et al1 investigated 
whether adding a statin to standard wound 
care and compression could improve venous 
stasis ulcer healing.
STUDY SUMMARY
ulcers are more likely to close  
when a statin is added to standard care
This randomized, double-blind, placebo-
controlled trial was performed at a large med-
ical center in the Philippines. It was designed 
to assess the efficacy and safety of simvastatin 
40 mg/d for venous ulcer healing when com-
bined with standard treatment (compression 
therapy, limb elevation, and standard wound 
care).1 
Researchers randomized 66 patients ages 
41 to 71 who’d had one or more venous ulcers 
for at least 3 months to receive either simvas-
tatin 40 mg/d (N=32) or an identical appear-
ing placebo (N=34). Patients were excluded 
if they were pregnant, had an ulcer that was 
infected or >10 cm in diameter, or were tak-
ing any medication that could interact with 
a statin. Patients were stratified according 
to ulcer diameter (≤5 cm and >5 cm). There 
was no statistically significant difference be-
tween the 2 groups in the duration of venous 
ulceration (3.80 years in the placebo group vs 
3.93 years in the simvastatin group) or inci-
dence of diabetes (5% in the placebo group vs 
3% in the simvastatin group).
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The primary outcome was the propor-
tion of patients whose ulcers completely 
healed at 10 weeks. Secondary outcomes 
were measures of the total surface area 
healed and healing time, and Dermatology 
Life Quality Index (DLQI) scores. Baseline 
ulcer diameter and surface area and DLQI 
scores were obtained prior to therapy. The 
same dermatologist, who was blinded to the 
patients’ assigned group, evaluated all pa-
tients every 2 weeks until wound closure or 
for a maximum of 10 weeks. 
Overall, 90% of the patients who re-
ceived simvastatin had complete ulcer clo-
sure at 10 weeks, compared with 34% of 
patients in the control group (relative risk 
[RR]=0.16; 95% confidence interval [CI], 
0.05-0.47; number needed to treat [NNT]=2). 
Among patients with ulcers ≤5 cm, 
100% of the ulcers healed in the simvas-
tatin group, compared to 50% in the control 
group (RR=0.10; 95% CI, 0.01-0.71; NNT=2). 
Perhaps more importantly, in patients with 
ulcers >5 cm, 67% of the ulcers in the simvas-
tatin group had closure with a mean healing 
time of 9 weeks, whereas none of the ulcers of 
this size closed in the control group (RR=0.33; 
95% CI, 0.12-0.84; NNT=1.5), and the mean 
healed area was significantly larger in pa-
tients who received simvastatin (28.9 cm2 vs 
19.6 cm2; P=.03). 
In addition, in the simvastatin group, 
healing times were significantly reduced 
(7.53±1.34 weeks vs 8.55±1.13 weeks) and 
quality of life (as evaluated by DLQI scoring) 
significantly improved compared to the con-
trol group.
Study dropouts (8%; 2 in the placebo 
group and 3 in the intervention group) were 
minimal. Using intention-to-treat analysis 
and worst-case scenarios for dropouts did 
not affect the primary outcome. There were 
no withdrawals for adverse reactions.
WHAT’S NEW
Statins offer significant benefits  
for treating venous stasis ulcers
This is the first human study to investigate the 
use of a statin in venous stasis ulcer healing. 
This intervention  demonstrated significant 
improvements in healing rate and time, a 
very small NNT for benefit, and improved pa-
tient quality of life compared to placebo.
CAVEATS
Results were found in a carefully selected 
group of patients
Many wounds will heal with compression 
therapy alone, as occurred in this study, 
where 50% of ulcers ≤5 cm treated with stan-
dard therapy healed, albeit at a somewhat 
slower rate. Adding another medication to 
the regimen when these patients generally 
have multiple comorbidities should always 
prompt caution. 
The study by Evangelista et al1 was per-
formed in a select population, and the ex-
clusion criteria included the use of some 
commonly prescribed medications, such as 
angiotensin-converting enzyme inhibitors. 
No data were collected on patient body mass 
index, which is a risk factor for delayed heal-
ing. The prevalence of obesity is lower in the 
Philippines than in the United States, and it 
is uncertain what role this difference would 
have in the statin’s effectiveness. Further 
studies, especially those conducted with a 
less selective population, would better clarify 
the generalizability of this intervention. 
We found the results of this study im-
pressive. The methods reported are rig-
orous and consistent with standard RCT 
methodologies. This is the only study of a 
statin in human venous stasis disease, but 
studies in animals—and studies of statins 
for other types of ulcers in humans—have 
consistently suggested benefit. It seems 
hard to argue against adding this low-cost, 
low-risk intervention. 
CHALLENGES TO IMPLEMENTATION
There are no known barriers to implementing 
this practice.                  JFP
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